Please check your internet connection and try again.
# Hepamerz (l-Ornithine l-Aspartate)
## Overview
Hepamerz is a combination of the amino acids l-ornithine and l-aspartate. It is primarily used in the management of hyperammonemia associated with liver insufficiency.
## Primary Indications
* Hepatic encephalopathy (manifestations of liver insufficiency).
## Adult Dosing
* **Intravenous (IV) Infusion:** Typically administered as a continuous infusion.
* **Dose:** 10-30 grams per day, often divided into 2-3 infusions.
* **Rate:** Not to exceed 5 grams per hour.
* **Duration:** Usually for 7-14 days, depending on clinical response and severity of hepatic encephalopathy.
* **Oral:** Available as granules or solution.
* **Dose:** 3-6 grams three times daily.
* **Maximum:** Generally not to exceed 18 grams per day.
*Specific dosing and infusion schedules may vary based on institutional protocols and patient response.*
## Pediatric Dosing
* There is limited established pediatric dosing for l-ornithine l-aspartate. Use in pediatric patients should be carefully considered and guided by expert opinion or specific clinical trial data if available.
## Dose Adjustments
* No specific dose adjustments are typically required for renal or hepatic impairment, as the drug is intended for patients with liver dysfunction. However, close monitoring of ammonia levels and clinical status is crucial.
## Contraindications
* Severe hypersensitivity to l-ornithine or l-aspartate.
* Advanced renal failure (especially with IV administration, due to potential for accumulation of amino acids).
## Adverse Effects
* **Gastrointestinal:** Nausea, vomiting, diarrhea, abdominal pain, bloating.
* **Neurological:** Dizziness, headache.
* **Other:** Increased serum creatinine (transient), fatigue, muscle pain.
* **Rare:** Allergic reactions.
## Key Drug Interactions
* No significant drug interactions are well-documented. However, caution should be exercised when co-administering with other medications that affect ammonia levels or are renally cleared.
## Monitoring
* **Serum Ammonia Levels:** Monitor periodically to assess treatment efficacy.
* **Hepatic Function Tests:** Monitor liver enzymes, bilirubin, and synthetic function (e.g., albumin, PT/INR).
* **Renal Function:** Monitor serum creatinine, especially with IV administration.
* **Clinical Status:** Monitor for improvement or worsening of hepatic encephalopathy symptoms (e.g., confusion, asterixis).
## Clinical Pearls
* l-Ornithine l-aspartate facilitates the detoxification of ammonia in the liver and peripheral tissues by stimulating the urea cycle and glutamine synthesis.
* Oral administration may be used for long-term management after initial IV treatment.
* Therapy is most effective when initiated early in the course of hepatic encephalopathy.
* Ensure adequate hydration with IV administration.
---
*Please verify the most current prescribing information and consult with a healthcare professional before making any treatment decisions.*
